Refining Vancomycin Use in Early CDI

A modified dosing approach could reshape recurrence prevention strategies.

1

Clostridioides difficile infection can recur after initial treatment, leading to significant morbidity and mortality.
2

The TAPER-V trial found a 4-week vancomycin pulse-and-taper regimen had a 74% probability of preventing recurrence compared to a 2-week regimen.
3

The trial involved 265 adult patients with a first episode or recurrence of C difficile infection across 12 Canadian hospitals.
4

Recurrence rates by day 56 were 15% for the pulse-and-taper group and 18% for the placebo taper group.
5

The researchers emphasized the need for further trials to optimize C difficile infection therapy, particularly comparing vancomycin and fidaxomicin.

1